Hossein Tabari, MD
Nephrology · Bogalusa, LANPI 1619032141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,499 and has fallen 70.3% since, to $446 in 2025.
Across 306 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$756
- AstraZeneca$755
- Novo Nordisk$581
- Astellas Pharma US Inc$562
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$541
- Amgen$384
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,85191%
- Education$4849%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 52 | $756 |
| AstraZeneca | 42 | $755 |
| Novo Nordisk | 37 | $581 |
| Astellas Pharma US Inc | 12 | $562 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $541 |
| Amgen | 22 | $384 |
| Pfizer | 25 | $312 |
| Amarin Pharma, Inc. | 17 | $271 |
| Merck | 10 | $159 |
| Exact Sciences | 8 | $149 |
| Vifor Pharma, Inc. | 8 | $143 |
| Boehringer Ingelheim | 6 | $92 |
| Lilly USA, LLC | 5 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| Akebia Therapeutics Inc | 3 | $61 |
| Dexcom, Inc. | 3 | $59 |
| AbbVie | 3 | $53 |
| Johnson & Johnson | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Abbott | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$5,335 in reported general payments places this provider in the 75th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $131,868 |
| FarxigaDapagliflozin Propanediol | 131 | $87,619 |
| LinzessLinaclotide | 110 | $77,715 |
| TrulicityDulaglutide | 70 | $57,850 |
| JanuviaSitagliptin Phosphate | 121 | $54,024 |
| OzempicSemaglutide | 50 | $51,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $37,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $37,227 |
| MounjaroTirzepatide | 35 | $35,885 |
| XifaxanRifaximin | 11 | $31,861 |
| XareltoRivaroxaban | 39 | $29,415 |
| JardianceEmpagliflozin | 46 | $27,647 |
| UbrelvyUbrogepant | 21 | $23,154 |
| EntrestoSacubitril/Valsartan | 34 | $21,473 |
| GemtesaVibegron | 35 | $17,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Lokelma | $755 | $134,196222 claims |
| PfizerEliquis | $312 | $131,868243 claims |
| AbbVieLinzess, Ubrelvy | $53 | $100,868131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $79 | $93,735105 claims |
| MerckJanuvia, Janumet | $159 | $60,085135 claims |
| Novo NordiskOzempic | $581 | $51,19650 claims |
| GSKTrelegy Ellipta | $756 | $37,34555 claims |
| Boehringer IngelheimJardiance, Tradjenta | $92 | $34,38172 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $541 | $31,86111 claims |
| Johnson & JohnsonXarelto | $46 | $29,41539 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $73 | $17,81035 claims |
| Astellas Pharma US IncMyrbetriq | $562 | $11,37014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Bogalusa
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Jon MaresCovington$103K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
- Michael LiuOpelousas$36K
- David PowersCovington$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.